We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HAL:NYSEHalliburton Company Analysis

Data as of 2026-05-20 - not real-time

$42.98

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Halliburton is trading near its 20‑day SMA of $41.03 with the price at $42.98, comfortably above the 50‑day SMA and well above the 200‑day SMA, indicating a strong bullish trend. The RSI of 64.7 and a bullish MACD histogram reinforce upward momentum, while the stock holds above its recent support of $38.78 and below a resistance near $43.37. Recent earnings surprised the market, delivering $0.55 EPS versus the $0.50 consensus and a modest revenue beat, prompting a 4% share price rally. Strategic expansion is underscored by a new on‑shore contract in Greenland, showcasing Halliburton’s capability in frontier markets and potentially opening a new revenue stream. Analyst sentiment is positive, with a “Buy” consensus and a median price target of $43, closely aligned with the current price. However, a discounted cash‑flow model values the company at roughly $24 per share, suggesting the market may be pricing in optimistic growth assumptions. The forward P/E of 14.9 is attractive relative to the trailing P/E of 23.7 and the industry average, indicating earnings are expected to accelerate. Dividend yield sits at 1.58% with a payout ratio under 40%, supporting the view that the dividend is sustainable. Debt remains elevated at a debt‑to‑equity of 74.6%, but the firm generates solid free cash flow and maintains a healthy cash balance. Volatility is elevated at ~32% over 30 days, yet the beta of ~0.36 points to lower systematic risk. In sum, Halliburton combines bullish technicals and short‑term catalysts with valuation concerns that temper longer‑term enthusiasm.
Investors should weigh the near‑term upside from earnings momentum and the Greenland contract against the substantial valuation premium and debt load when forming a view on the stock.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Q1 earnings beat and 4% price jump
  • Bullish technical setup (SMA crossover, RSI, MACD)
  • New Greenland contract expanding geographic exposure

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Current price above DCF fair value indicating overvaluation
  • Attractive forward P/E suggesting earnings growth potential
  • Sector cyclicality and oil price volatility

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Sustainable dividend with low payout ratio
  • Strategic positioning in frontier markets and digital services
  • Strong free cash flow generation despite high debt

Key Metrics & Analysis

Financial Health

Revenue Growth-0.30%
Profit Margin6.95%
P/E Ratio23.7
ROE14.63%
ROA7.38%
Debt/Equity74.65
P/B Ratio3.3
Op. Cash Flow$2.8B
Free Cash Flow$2.0B
Industry P/E22.3

Technical Analysis

TrendBullish
RSI64.7
Support$38.78
Resistance$43.37
MA 20$41.03
MA 50$38.82
MA 200$30.31
MACDBullish
VolumeDecreasing
Fear & Greed Index89.32

Valuation

Fair Value$24.12
Target Price$42.84
Upside/Downside-0.33%
GradeOvervalued
TypeBlend
Dividend Yield1.58%

Risk Assessment

Beta0.37
Volatility31.93%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.